Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 15 May 2024 17:52:07 +0200Tue, 06 Feb 2024 15:17:30 +0100Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, Efgartigimod alfa, decision type: W: decision granting a waiver in all age groups for all conditions or indications, PIP number: P/0013/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip09-22Opinion/decision on a Paediatric investigation plan (PIP): Vyvgart, Efgartigimod alfa, decision type: W: decision granting a waiver in all age groups for all conditions or indications, PIP number: P/0013/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-002597-pip09-22Tue, 06 Feb 2024 15:17:30 +0100Human medicineHuman medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/vyvgartHuman medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 6, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/vyvgartWed, 20 Dec 2023 12:41:00 +0100Human medicineVyvgart : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5849_en_3.pdfVyvgart : EPAR - Product Informationhttps://www.ema.europa.eu/system/files/documents/product-information/ema-combined-h-5849_en_3.pdfWed, 20 Dec 2023 12:38:00 +0100Human medicine